iso-alpha-Cedrene is a cedarwood-type sesquiterpene hydrocarbon that appears to align with the alpha-funebrene naming used in public chemical databases. In AromaForge it matters because one reviewed Chinese cedarwood-thuja oil record is strongly iso-alpha-cedrene dominant, making it a meaningful chemotype marker even though the broader public literature is thin. The evidence here is strongest for identity and occurrence, with only light ecological or composition literature and no strong constituent-specific human safety or efficacy base, so the record should remain conservative and chemistry-led.
Aroma and practical use
- Use the recorded woody, cedarwood, dry, resinous, cedar-like, resin descriptors to explore a blend's scent character; perceived strength also depends on the other ingredients.
- Read the route, preparation and experimental context before using a study finding to choose an oil.
Reported benefits and effects
Findings retain their study context. An animal or laboratory result describes that experiment.
The reviewed Chinese cedarwood-thuja supplier profile lists iso-alpha-cedrene at 32% in Chamaecyparis funebris wood oil, supporting archive treatment of an iso-alpha-cedrene or alpha-funebrene-rich chemotype.
The reviewed Chinese cedarwood-thuja supplier profile lists iso-alpha-cedrene at 32% in Chamaecyparis funebris wood oil, supporting archive treatment of an iso-alpha-cedrene or alpha-funebrene-rich chemotype.
This reference does not establish a therapeutic result or a safe use level for a custom oil blend.
A 2011 vector-ecology paper on Cupressus funebris wood oil reported the oil was characterized mainly by alpha-cedrene, cedrol, beta-cedrene, and thujopsene, which helps frame iso-alpha-cedrene as a related cedarwood sesquiterpene in this chemistry family rather than as a well-isolated pharmacology target.
A 2011 vector-ecology paper on Cupressus funebris wood oil reported the oil was characterized mainly by alpha-cedrene, cedrol, beta-cedrene, and thujopsene, which helps frame iso-alpha-cedrene as a related cedarwood sesquiterpene in this chemistry family rather than as a well-isolated pharmacology target.
This reference does not establish a therapeutic result or a safe use level for a custom oil blend.
A 2012 phytochemical paper on different plant parts of Ferula ferulioides reported alpha-funebrene at 10.1% in the leaf essential oil and 7.4% in the flower essential oil, showing the compound appears in non-cedar volatile systems as well.
A 2012 phytochemical paper on different plant parts of Ferula ferulioides reported alpha-funebrene at 10.1% in the leaf essential oil and 7.4% in the flower essential oil, showing the compound appears in non-cedar volatile systems as well.
This reference does not establish a therapeutic result or a safe use level for a custom oil blend.
Use concerns and concentration limits
Sensitization concernNot flagged
Not flagged in the current model. This is not proof of absence or unrestricted safety.
Phototoxicity concernNot flagged
Not flagged in the current model. This is not proof of absence or unrestricted safety.
Oxidation concernNot flagged
Not flagged in the current model. This is not proof of absence or unrestricted safety.
Penetration enhancementNot flagged
Not flagged in the current model. This is not proof of absence or unrestricted safety.
No numeric constituent-specific use limit is available here. Missing is not an unrestricted-use clearance.
No constituent-specific IFRA limit, RIFM safety assessment, dermal restriction, or human tolerability study for isolated iso-alpha-cedrene or alpha-funebrene was verified in this pass.
This reference does not establish a therapeutic result or a safe use level for a custom oil blend.
Because the accessible literature is largely analytical and taxonomic, any benefit-style consumer copy would currently overstate the evidence.
This reference does not establish a therapeutic result or a safe use level for a custom oil blend.
Constituents it may interact with
No constituent-pair interaction is recorded for this identity. The report does not assume either amplification or incompatibility.
What this report cannot establish
- A reported constituent percentage does not establish an effective human therapeutic dose or the amount absorbed into the body.
- The presence of a constituent does not guarantee a clinical benefit, rash treatment or sleep improvement from a custom blend.
- An unflagged concern or missing use limit does not establish safety for ingestion, inhalation, skin exposure or a particular person.
- A candidate constituent interaction does not establish that two oils amplify one another at the selected proportions.
- Constituent descriptors alone do not establish a precise top, heart or base lifetime in a finished blend.
Known data gaps (7)
- The archive name `iso_alpha_cedrene` appears to map to public alpha-funebrene identity data, but direct source text using both names interchangeably is still limited.
- No human clinical, isolated-compound pharmacology, or constituent-specific safety-assessment literature was verified for iso-alpha-cedrene in this pass.
- Most available evidence is occurrence-focused rather than effect-focused.
- An IFRA Standard for Cedrene (Amendment 49, 2020; driven by dermal sensitization) exists, but it explicitly scopes CAS 11028-42-5 (mixed cedrene), 469-61-4 (alpha-cedrene), and 546-28-1 (beta-cedrene) - not CAS 50894-66-1. NIST identifies 50894-66-1 as a distinct stereoisomer (di-epi-alpha-cedrene / alpha-funebrene), so this Standard cannot be confirmed to cover iso-alpha-cedrene specifically. The previously listed 25% dermal limit and unqualified sensitizing:true were uncited placeholders and have been cleared pending a constituent-specific assessment.
- Second-pass 2026-07-13 retry tried a direct CAS/name search ('alpha-funebrene' OR 'iso-alpha-cedrene' + IFRA/RIFM sensitization) and an ECHA CL Inventory lookup for CAS 50894-66-1; results again returned only identity/supplier listings (ChemicalBook, Good Scents) and general IFRA Cedrene Standard documentation already noted as not scoping this CAS, with no ECHA CLP classification entry found for 50894-66-1. No authoritative constituent-specific sensitization or dermal-limit source was found; fields remain null/false.
- No constituent-specific numeric dermal reference is available here.
- Some findings do not record an explicit exposure route; consult the linked study before applying them to a use.